{"preliminary_commentary":{"by_channel":{"bluesky_thread":13,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06049576\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"NCT06049576","nct_id":"NCT06049576","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06049576. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for cycles 1-4. Beginning cycle 5, patients receive nivolumab over 30 minutes on day 1 of each cycle. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and stool sample collection and undergo CT and/or bone scan and/or MRI on trial.","label":"Arm 1 (nivolumab and ipilimumab)","type":"ACTIVE_COMPARATOR"},{"description":"Patients receive nivolumab IV over 30 minutes on day, ipilimumab IV over 30 minutes on day 1, and camu camu PO QD continuously with each cycle. Cycles repeat every 3 weeks for cycles 1-4. Beginning cycle 5, patients receive nivolumab over 30 minutes on day 1, and camu camu PO QD of each cycle. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and stool sample collection and undergo CT and/or bone scan and/or MRI on trial.","label":"Arm 2 (nivolumab, ipilimumab, camu camu)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2027-05-25","type":"ESTIMATED"},"conditions":["Clear Cell Renal Cell Carcinoma","Sarcomatoid Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8"],"enrollment":{"count":31,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Specimen Collection"],"type":"PROCEDURE"},{"name":"Bone Scan","otherNames":["Bone Scintigraphy"],"type":"PROCEDURE"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","CT","CT Scan","tomography"],"type":"PROCEDURE"},{"name":"Ipilimumab","otherNames":["Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody","BMS-734016","Ipilimumab Biosimilar CS1002","MDX-010","MDX-CTLA4","Yervoy"],"type":"BIOLOGICAL"},{"name":"Magnetic Resonance Imaging","otherNames":["Magnetic Resonance","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging"],"type":"PROCEDURE"},{"name":"Myrciaria dubia Prebiotic Supplement","otherNames":["Camu Camu Prebiotic","Camu-camu Prebiotic","Myrciaria dubia based Prebiotic","Myrciaria dubia Supplement"],"type":"DRUG"},{"name":"Nivolumab","otherNames":["BMS-936558","CMAB819","MDX-1106","NIVO","Nivolumab Biosimilar CMAB819","ONO-4538","Opdivo"],"type":"BIOLOGICAL"}],"last_update":"2026-10-08","lead_sponsor":"City of Hope Medical Center","official_title":"Combination Nivolumab and Ipilimumab With and Without Camu Camu in First Line Treatment of Metastatic Renal Cell Carcinoma","overall_status":"SUSPENDED","phases":["PHASE1"],"primary_completion_date":{"date":"2027-05-25","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Abundance of ruminococcus in the stool","timeFrame":"From baseline to week 12 of therapy"}],"references":[],"start_date":{"date":"2023-10-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT06049576"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06049576"}